News | March 17, 2023
Mindset Pharma to defend against lawsuit filed by Reunion Neurosciences
Mindset disagrees with and denies the allegations set forth from Reunion.
Mindset disagrees with and denies the allegations set forth from Reunion.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Expanding precision medicine, ARTIS icono is designed to enable a wide procedure mix in a single interventional suite
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
To address the preventive & primary healthcare delivery gaps in India
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Subscribe To Our Newsletter & Stay Updated
